There is a clear need in drug development to reduce attrition from clinical studies especially due to toxicology. It was estimated that a 5-10% improvement in the attrition rate could double the output of marketed drugs. This meeting aims to provide practical insights into some of the recent
preclinical approaches and strategies which have been developed to help the chemist design safer medicines.
This meeting is targeted at all those who are involved in the lead identification and lead optimisation processes in Drug Discovery and interested in furthering their knowledge of current and emerging approaches to designing safer Drug Candidates